CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Atrandi Biosciences›
Library
Atrandi Biosciences

Atrandi Biosciences

Atrandi Biosciences builds instruments and kits for high-throughput single-cell analysis using semi-permeable capsules and droplet microfluidics.

Operating headquarters
Vilnius, LT🇱🇹
Founded
2016
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Atrandi Biosciences - Library

Official pages and third-party coverage in one index.

atrandi.com·30 items across 24 mapped pages · Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

6 pages
  1. Applications/application

    Explore single-cell applications for genomics, high-throughput screening, cultivation, and advanced multi-omics workflows.

  2. DNA and RNA co-sequencing/application/dna-rna-co-sequencing

    Perform DNA and RNA co-sequencing at single-cell level with solutions designed for accurate multi-omics analysis.

  3. High-Throughput Screening/application/high-throughput-screening

    High-throughput screening for scalable single-cell analysis, enabling faster discovery and efficient testing workflows.

  4. Microfluidics/application/microfluidics

    Droplets are collected in tubes allowing further manipulation with specialized microfluidic modules

Blog

6 pages
  1. Blog | Resource Hub/blog

    Read our latest blog posts on single-cell technology and droplet microfluidics.

  2. Bringing the Invisible to Light: Bigelow Scientists Find Unexpected Viral Members of Ocean Community/news/bringing-the-invisible-to-light

    With a novel high-throughput genomic analysis workflow powered by Atrandi’s Semi-Permeable Capsule technology, scientists glean new insights from single cells in environmental samples At the Bigelow Laboratory for Ocean Sciences, scientists have...

  3. Droplet microfluidics-based isolation and screening of riboflavin-producing lactic acid bacteria/news/droplet-microfluidics-based-isolation,-adaptation,-and-screening

    Publication Summary LWT February 1, 2026 Authors: Hang Xiao, Anders Peter Wätjen, Guillermo-Eduardo Sedó Molina, Egon Bech Hansen, Miguel Tovar, Claus Heiner Bang-Berthelsen Challenge addressed: Plant-based dairy alternatives (PBDA) are nutritionally...

  4. From Droplets to Capsules: Atrandi Opens a New Chapter in Single-Cell Multiomics/news/from-droplets-to-capsules:-atrandi-opens-a-new-chapter-in-single-cell-multiomics

    On October 1st, we opened the doors to Atrandi’s new headquarters in Vilnius – not just a building, but a milestone in our journey. What started as a handful of scientists working in a small lab has become a globally competitive company shaping the

Press

6 pages
  1. Adam Cribbs: Against Easy Answers In Single-Cell Biology/news/adam-cribbs-against-easy-answers-in-single-cell-biology

    Scientific Spotlight: Prof. Adam Cribbs at the University of Oxford, where single-cell genomics meets the tissues and questions the field keeps avoiding.

  2. Always One More Question: a Co-founder Story/news/always-one-more-question-a-co-founder-story

    A co-founder story: Atrandi CEO Juozas Nainys on curiosity, discovery, and why every new instrument opens a new layer of questions in single-cell biology.

  3. An Unpredictable World: a Co-founder Story/news/an-unpredictable-world-a-co-founder-story

    Atrandi co-founder and CTO Karolis Leonavičius on invention without a eureka moment, building for overlooked fields, and hoping for an unpredictable future.

  4. Atrandi and Bigelow SCGC collaborate on bioinformatics services/news/atrandi-and-bigelow-scgc-collaborate-on-bioinformatics-services

    Atrandi Biosciences and Bigelow Laboratory's Single Cell Genomics Center (SCGC) have teamed up to complement the high-throughput single-cell microbial DNA sequencing workflow with bioinformatics services VILNIUS, Lithuania and BOOTHBAY, ME, US | February...

About

1 page
  1. About Us/about

    Learn about Atrandi’s mission, team, and innovations, enabling breakthroughs in single-cell research and biotechnology.

Contact

1 page
  1. Contact Us/contact

    Contact us now! Fill out the contact form, and Atrandi expert will get back to you ASAP.

Homepage

2 pages
  1. Homepage/

    Advanced single-cell solutions by Atrandi. Discover high-throughput single-cell technologies for genomics, screening, and biological innovation.

  2. Homepage/

    Advanced single-cell solutions by Atrandi. Discover high-throughput single-cell technologies for genomics, screening, and biological innovation.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Droplet Genomics privacy policy defines how we collect, use, communicate, disclose, and use personal information.

Terms & Conditions

1 page
  1. Terms and Conditions of Sale/terms-conditions

    Atrandi Biosciences Terms and Conditions of Sale.

Not yet classified

1 page
  1. atrandi.com/

    Advanced single-cell solutions by Atrandi. Discover high-throughput single-cell technologies for genomics, screening, and biological innovation.

Coverage

5 items
  1. Atrandi Biosciences appoints distribution partners across Asia-Pacificatrandi.com/news/atrandi-is-now-across-asia-pacific

    eight distribution partners appointed across Asia-Pacific

    Sep 2026 · Atrandi BiosciencesNews article

  2. Webinar: high-throughput microbial screening and single-cell genomicsatrandi.com/news/webinar-high-throughput-microbial-screening

    Atrandi Biosciences announced webinars scheduled for September 15–17. The sessions demonstrate workflows for high-throughput microbial screening and single-cell genomics.

    Sep 2026 · Atrandi BiosciencesNews article

  3. Atrandi Biosciences Expands Leadership Teamjournalforclinicalstudies.com/atrandi-biosciences-expands-leadership-team-to-accelerate-global-adoption-of-capsule-based-single-cell-technology/

    Atrandi Biosciences names Sam Ropp chief commercial officer and Susan Tousi chair of its board. The article provides no further details about the appointments.

    May 2026 · Journal for Clinical StudiesNews article

  4. Atrandi Biosciences Redefines Single-Cell Multiomics with Expanded SPC Innovator Kit Portfoliobiospace.com/press-releases/atrandi-biosciences-redefines-single-cell-multiomics-with-expanded-spc-innovator-kit-portfolio

    Atrandi Biosciences announces an expanded SPC Innovator Kit portfolio featuring larger 170- and 300-micrometer options. The supplied text notes that the product page still describes the 300-micrometer option as in development.

    Feb 2026 · BioSpaceNews article